


### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hour per response: 4.0

1. Issuer's Identity		
1. Issuel S lucillity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001321834	None	© Corporation
Name of Issuer	Akers Biosciences Inc	C Limited Partnership
Akers Biosciences, Inc.		C Limited Liability Company
Jurisdiction of Incorporation/Organization	_	C General Partnership
NEW JERSEY		C Business Trust
Year of Incorporation/Organization	on	C Other
<ul><li>Over Five Years Ago</li></ul>		
O Within Last Five Years (Specify Year)		
C Yet to Be Formed		





Clarification of Response (if Necessary)					
President and Chief Executive Officer					
Last Name	First Name		Middle Name		
Silverman	Joshua				
Street Address 1		Street Address 2	_		
201 Grove Road					
City	State/Province	e/Country	ZIP/Postal Code		
Thorofare	NEW JERSI	EY	08086		
			-1.		
Relationship: Ex	cecutive Officer	Director	Promoter		
Clarification of Despense (if Nesser	20071				
Chairman of the Poord of Direct					
Chairman of the Board of Direct	ors				
Last Name	First Name		Middle Name		
White	Bill		J.		
Street Address 1		Street Address 2			
201 Grove Road					
City	State/Province	e/Country	ZIP/Postal Code		
Thorofare	NEW JERSE	EY	08086		
			-1		
Relationship: Ex	ecutive Officer	<b>▽</b> Director	Promoter		
		(Months)	F		
Clarification of Response (if Neces	ssary)				
Last Name	First Name		Middle Name		
Schroeder	Robert		C.		
Street Address 1		Street Address 2			
201 Grove Road					
City	State/Province	e/Country	ZIP/Postal Code		
Thorofare	NEW JERSE	EY	08086	$\overline{}$	
Relationship: Ex	xecutive Officer	<b>▽</b> Director	Promoter		
Clarification of Response (if Neces	ssary)				

# 4. Industry Group

~ A	griculture	Health Care	0	Retailing
	Banking & Financial Services	C Biotechnology		Restaurants
	Commercial Banking	C Health Insurance C Hospitals & Physici		
	O Insurance	C Pharmaceuticals	u113	Technology
9	O Investing	<b>6</b> Other Health Care		Computers
9	Investment Banking			C Telecommunications
3	Pooled Investment Fund			C Other Technology
3	Other Banking & Financial  Services	Manufacturing		Travel
Ов	Business Services	Real Estate		Airlines & Airports
	Cnergy	C Commercial		C Lodging & Conventions
	Coal Mining	C Construction		O Other Travel
9	C Electric Utilities	C REITS & Finance	_	Other Travel
	Energy Conservation	C Residential		Other
9	Environmental Services	Other Real Estate		
	Oil & Gas			
3	Other Energy			
5.	Issuer Size			
2020	nue Range	1044	Net Asset Val	
C	No Revenues			et Asset Value
C	\$1 - \$1,000,000	_	\$5,000,000	
0	\$1,000,001 - \$5,000,000	7040	000,001 - \$25	
C	\$5,000,001 - \$25,000,000	140	,000,001 - \$5	
0	\$25,000,001 - \$100,000,000	140	,000,001 - \$1	
0	Over \$100,000,000		er \$100,000,0	
•	Decline to Disclose	100	cline to Discl	ose
C	Not Applicable	C No	Applicable	
	Federal Exemption(s) a	nd Exclusion(s)	Claime	ed (select all that
ap	ply)			
	Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505		
П	Rule 504 (b)(1)(i)	Rule 506(b)		
П	Rule 504 (b)(1)(ii)	Rule 506(c)		
П	Rule 504 (b)(1)(iii)	Securities Act Section	n 4(a)(5)	
		г		. 2(a)
<u></u>		Investment Compar	y Act Section	n 3(c)
7 .	Type of Filing			
1.	Type of Filing		_	
V	New Notice Date of First Sale	2020-11-11	Firs	t Sale Yet to Occur
П	Amendment			
8.	Duration of Offering			
Does	the Issuer intend this offering to last mo	ore than one year?	C	Yes © No
0	T (-) - f O ''' - O (		111	
•	Type(s) of Securities Of	iered (select al	tnat ap	oply)
	Pooled Investment Fund Interests	quity		
П	Tenant-in-Common Securities D	ebt		

Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon  Exercise of Option, Warrant or Other Right to Acquire  Security  Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?  Yes  No
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside investor  S  USD
12. Sales Compensation
Recipient Recipient CRD Number None  Katalyst Securities LLC
(Associated) Broker or Dealer CRD
(Associated) Broker or Dealer None Number Number
Street Address 2
630 THIRD AVENUE STH FLOOR
City State/Province/Country ZIP/Postal Code  NEW YORK NEW YORK 10017
State(s) of Solicitation All States Foreign/Non-US
State(s) of Soficiation [ ] Thi States [ ] Toreign/Ton CS
CALIFORNIA
CALIFORNIA CONNECTICUT FLORIDA
CONNECTICUT
CONNECTICUT FLORIDA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA
CONNECTICUT FLORIDA GEORGIA ILLINOIS INDIANA IOWA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK  OHIO
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK  OHIO  PENNSYLVANIA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK  OHIO  PENNSYLVANIA
CONNECTICUT FLORIDA GEORGIA ILLINOIS INDIANA IOWA MARYLAND MASSACHUSETTS MICHIGAN NEW JERSEY NEW YORK OHIO PENNSYLVANIA SOUTH DAKOTA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK  OHIO  PENNSYLVANIA
CONNECTICUT FLORIDA GEORGIA ILLINOIS INDIANA IOWA MARYLAND MASSACHUSETTS MICHIGAN NEW JERSEY NEW YORK OHIO PENNSYLVANIA SOUTH DAKOTA
CONNECTICUT  FLORIDA  GEORGIA  ILLINOIS  INDIANA  IOWA  MARYLAND  MASSACHUSETTS  MICHIGAN  NEW JERSEY  NEW YORK  OHIO  PENNSYLVANIA  SOUTH DAKOTA   13. Offering and Sales Amounts

Represents 9,765,933 shares of common stock or pre-funded warrants and warrants to purchase 9,765,933 shares of common stock at \$2.06 per share.

14.	nvestors	
	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,  Number of such non-accredited investors who already have invested in the offering  Regardless of whether securities in the offering have been or may be sold	56

## 15. Sales Commissions & Finders' Fees Expenses

number of investors who already have invested in the offering:

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$ 1174355	USD	<b>Estimate</b>
Finders' Fees	\$ 0	USD	Estimate

Clarification of Response (if Necessary)

In addition to the sales commission noted above, the placement agent also received a warrant to purchase 390,368 shares of Issuer's common stock at \$1.85 per share.

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0	USD	П	Estimate

#### Signature and Submission

Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Akers Biosciences, Inc.	/s/ Stuart Benson	Stuart Benson	Chief Financial Officer	2020-11-24